ArticleFrontiers in antibiotics2025
A case report of drug-drug interaction between voriconazole and simnotrelvir/ritonavir.
Article in Frontiers in antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Co-administration of simnotrelvir/ritonavir with voriconazole should be avoided, as stated in the product insert of simnotrelvir/ritonavir, due to the anticipated decrease in the plasma concentration of voriconazole. Currently, there are no published reports regarding a pharmacokinetic interaction between simnotrelvir/ritonavir and voriconazole. We present the case of an 88-year-old man with pulmonary aspergillosis and coronavirus disease 2019 (COVID-19) co-infection treated concurrently with voriconazole and simnotrelvir/ritonavir. Prior to initiating simnotrelvir/ritonavir, two trough concentrations of voriconazole were measured, yielding values of 2.8 and 2.6 mg/L. After 2 days of co-administration with simnotrelvir/ritonavir, the voriconazole trough concentration rose to 6.0 mg/L. The voriconazole dose was subsequently reduced by 25%, and simnotrelvir/ritonavir was discontinued after completion of the standard 5-day course. A week after voriconazole dose reduction (4 days after simnotrelvir/ritonavir withdrawal), the trough concentration was measured again and was found to be 3.5 mg/L. This case indicates that the trough concentration of voriconazole increased significantly during co-administration with simnotrelvir/ritonavir. Moreover, the interaction persisted even after discontinuation of simnotrelvir/ritonavir, necessitating dynamic dose adjustments guided by therapeutic drug monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.